Immucor CEO De Chirico
This article was originally published in The Gray Sheet
Chairman Edward Gallup will take over CEO duties "on an interim basis" from Gioacchino De Chirico while the firm conducts an internal investigation related to "alleged improper cash payments" by Immucor and other firms, made "in exchange for favorable contract awards" by an Italian hospital, the firm says. De Chirico will retain his other title of president during the investigation, which parallels a criminal investigation by Italian authorities. The hospital administrator apparently had received an improperly documented payment of about $17,000 to organize an Immucor-sponsored convention, according to the company...
You may also be interested in...
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.
The US FDA released five device-related close-out letters in March.